MARKET

KDNY

KDNY

Chinook Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.75
-0.35
-2.05%
Closed 16:00 06/11 EDT
OPEN
17.26
PREV CLOSE
17.10
HIGH
17.58
LOW
16.67
VOLUME
251.00K
TURNOVER
--
52 WEEK HIGH
21.68
52 WEEK LOW
10.50
MARKET CAP
747.32M
P/E (TTM)
-2.5330
1D
5D
1M
3M
1Y
5Y
BRIEF-Chinook Therapeutics Announces Promotions Of Tom Frohlich To Chief Operating Officer And Andrew King, D.V.M, Ph.D., To Chief Scientific Officer
reuters.com · 3d ago
Chinook Therapeutics names new COO and CSO
Chinook Therapeutics (KDNY) announces the promotions of Tom Frohlich and Andrew King to the roles of chief operating officer ((COO)) and chief scientific officer ((CSO)).Frohlich is currently serving as the company's chief
Seekingalpha · 3d ago
Chinook Therapeutics Announces Promotions of Tom Frohlich to Chief Operating Officer and Andrew King, D.V.M, Ph.D., to Chief Scientific Officer
SEATTLE, June 09, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that To...
GlobeNewswire · 3d ago
Chinook Therapeutics' BION-1301 Shows Reduction In 24-Hour Proteinuria In Nephropathy Trial
Benzinga · 4d ago
Chinook Therapeutics reports interim BION-1301 data in patients with IgA Nephropathy
Chinook Therapeutics ([[KDNY]] +10.2%) presents data from its ongoing phase 1/2 study of BION-1301 in patients with IgA Nephropathy (IgAN). BION-1301 has been well-tolerated, with no treatment-related or severe adverse events,
Seekingalpha · 4d ago
The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7)
Benzinga · 4d ago
BRIEF-Chinook Therapeutics Presents Bion-1301 Interim Phase 1/2 Data In Patients With Iga Nephropathy (Igan) At The 58Th Era-Edta Virtual Congress
reuters.com · 4d ago
Chinook Therapeutics Highlights Presentation Of BION-1301 Interim Phase 1/2 Data In Patients With IgA Nephropathy At The 58th ERA-EDTA Virtual Congress
BION-1301 has been well-tolerated to date in patients with IgAN, with no serious adverse events (SAEs) or treatment discontinuations due to adverse events   Pharmacokinetics (PK) of BION-1301 observed in
Benzinga · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KDNY. Analyze the recent business situations of Chinook Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KDNY stock price target is 31.57 with a high estimate of 40.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 144
Institutional Holdings: 24.96M
% Owned: 55.94%
Shares Outstanding: 44.62M
TypeInstitutionsShares
Increased
15
816.70K
New
8
73.32K
Decreased
26
638.15K
Sold Out
7
519.99K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.29%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Chairman/President/Chief Executive Officer/Director
Eric Dobmeier
Chief Financial Officer
Eric Bjerkholt
Chief Operating Officer
Tom Frohlich
Chief Scientific Officer
Andrew King
Other
Alan Glicklich
Lead Director/Independent Director
Jerel Davis
Independent Director
Srinivas Akkaraju
Independent Director
William Greenman
Independent Director
Michelle Griffin
Independent Director
Ross Haghighat
Independent Director
Dolca Thomas
No Data
  • All
  • Financials
  • Insiders
More
About KDNY
Chinook Therapeutics, Inc., formerly Aduro Biotech, Inc., is a clinical-stage biotechnology company. The Company develops precision medicines for kidney diseases. The Company’s products focus on severe chronic kidney disorders. The Company assembled a portfolio of precision medicines product candidates designed to address severe chronic kidney diseases. Its development programs consist of atrasentan, BION-1301 and CHK-336. Atrasentan, a potent and selective endothelin receptor antagonist that the Company is developing for treatment of primary glomerular diseases, including IgAN. IgAN is a serious progressive autoimmune disease of the kidney. BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase 1b trial for IgA nephropathy. CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other chronic kidney diseases, including polycystic kidney disease.

Webull offers kinds of Chinook Therapeutics Inc stock information, including NASDAQ:KDNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KDNY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KDNY stock methods without spending real money on the virtual paper trading platform.